利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.019 秒)

    ANTIBODIES THAT ARE CAPABLE OF SPECIFICALLY BINDING TISSUE FACTOR PATHWAY INHIBITOR
    5.
    发明公开
    ANTIBODIES THAT ARE CAPABLE OF SPECIFICALLY BINDING TISSUE FACTOR PATHWAY INHIBITOR 审中-公开
    ANTIKÖRPERFÜRSPEZIFISCHE BINDUNG DES GEWEBEFAKTOR-PATHWAY-INHIBITORS

    公开(公告)号：EP2588499A1

    公开(公告)日：2013-05-08

    申请号：EP11729297.9

    申请日：2011-06-30

    申请人： Novo Nordisk A/S

    发明人： HILDEN, Ida ,  CLAUSEN, Jes Thorn ,  PETERSEN, Lars Christian ,  SØRENSEN, Brit Binow ,  PETERSEN, Helle Heibroch

    IPC分类号： C07K16/38 ,  A61K39/395 ,  A61P7/04

    摘要： The invention relates to antibodies that are capable of specifically binding tissue factor pathway inhibitor (TFPI), neutralising free TFPI and reducing the clotting time of blood. Furthermore, the invention relates to polynucleotides that encode such antibodies and to cells that comprise the polynucleotides or that express the antibodies of the invention. Such antibodies have utility in the treatment of subjects with a coagulopathy, alone as well as in combination with a second agent.

    摘要翻译： 本发明涉及能够特异性结合组织因子途径抑制剂（TFPI），中和游离TFPI并降低血液凝固时间的抗体。 此外，本发明涉及编码这种抗体的多核苷酸和包含多核苷酸或表达本发明的抗体的细胞。 这样的抗体可用于治疗具有凝血病的受试者，单独和与第二药剂组合。

    ANTI-HUMAN INTERLEUKIN-20 ANTIBODIES
    10.
    发明公开
    ANTI-HUMAN INTERLEUKIN-20 ANTIBODIES 审中-公开
    抗人白细胞介素20ANTIKÖRPER

    公开(公告)号：EP2297203A1

    公开(公告)日：2011-03-23

    申请号：EP09772421.5

    申请日：2009-06-30

    申请人： Novo Nordisk A/S

    发明人： PASS, Jesper ,  ØSTERGAARD, Søren ,  CLAUSEN, Jes Thorn

    IPC分类号： C07K16/24

    CPC分类号： C07K16/244 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76

    摘要： Anti-human IL20 monoclonal antibodies that can reduce IL20 mediated activation of both IL20R1/IL20R2 and IL22R1/IL20R2 receptor complexes in one or more species, including humans, are described, as well as antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules designed or derived from such antibodies, and methods or producing such antibodies or other antigen-binding molecules. Such antibodies or other antigen-binding molecules can be used for treat-ing various diseases and disorders, including autoimmune or inflammatory diseases or disorders.

    摘要翻译： 描述了可以减少包括人在内的一种或多种物种中IL20介导的IL20R1 / IL20R2和IL22R1 / IL20R2受体复合物的IL20介导的活化的抗人IL20单克隆抗体，以及抗原结合分子，例如抗原结合 抗体片段，抗体衍生物和由此类抗体设计或衍生的多特异性分子，以及方法或产生此类抗体或其他抗原结合分子。 这样的抗体或其它抗原结合分子可用于治疗各种疾病和病症，包括自身免疫性或炎性疾病或病症。